The main objective of this study is to assess the usability and efficacy of receiving therapy with the peaditric exoskeleton ATLAS 2030in children with gait impairment due to a cerebral palsy condition. It will be valued the impact of rehabilitation with the exoskeleton at the physical level on parameters such as joint range, spasticity, as well as the impact in quality of life. It is also assessed the impact at the level of functionality of the participants, through the administration of different functional assessment scales.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Gross Motor Function Classification System
Timeframe: Every month up to 3 months
To quantify number of steps taken within the device
Timeframe: Every session up to 28 sessions
Changes in joint range of motion
Timeframe: Every session up to 28 sessions
Changes in spasticity
Timeframe: Every session up to 28 sessions
Changes in the Six-Minute Walking Test performance
Timeframe: Every month up to three months
Changes in the 10 Meters Walking Test performance
Timeframe: Every month up to three months
Changes in the time walked within the device
Timeframe: Three months
Changes in the Gross Motor Function Measure 88 for children with cerebral palsy (GMFM-88)
Timeframe: Every month up to three months
Changes in the Functional Independence Measure for Children (WeeFim)
Timeframe: Every month up to three months
Cerebral Palsy Quality of Life
Timeframe: Three months